Study Overview and Design

The SCOPE (Satellite Cell Obstetrical PlExus) study is an observational study led by Dr. Marion Delpont, Head of Pediatric Orthopedics at the University Hospital of Montpellier (CHU Montpellier) in France. It commenced on October 17, 2022, and concluded on June 25, 2025. The study aimed to isolate and culture muscle satellite cells from the shoulder rotator muscles of infants with Obstetrical Brachial Plexus Palsy (OBPP) to evaluate their regenerative capacity. The study included children aged 2 to 15 with OBPP who were scheduled for shoulder arthrolysis or muscle transfer. Muscle tissue was collected during surgery to obtain satellite cells. This represents a rare and systematic attempt to apply a cell-biological approach in this field.

Disease Background and Unmet Needs

OBPP is a nerve injury caused by traction or rupture of the brachial plexus during childbirth, occurring in approximately 1 to 3 cases per 1,000 births. Current standard treatments include physical therapy, botulinum toxin (BoNT-A) injections, nerve grafting, and nerve transfer. However, these treatments primarily focus on nerve pathway reconstruction. There are currently no treatments that regenerate the muscle itself at the cellular level, which has already undergone atrophy and fibrosis due to nerve damage. This is a major bottleneck in achieving long-term functional recovery.

Scientific Significance of a Satellite Cell-Based Disease Model

Satellite cells are tissue-specific stem cells residing in adult skeletal muscle, which are activated upon muscle fiber damage and play a crucial role in muscle regeneration. The SCOPE study is a systematic study that quantitatively compares the regenerative capacity of satellite cells from OBPP patients with those from normal muscle in vitro. By establishing this disease-specific cell model, it can be used as a preclinical platform for drug screening, gene editing, and cell therapy strategies. In combination with the time-dependent decrease in MyoD expression observed in previous studies, it can also contribute to the establishment of an optimal therapeutic window.

Industrial and Investment Context

The global stem cell and regenerative medicine market is projected to grow from approximately USD 16.7 billion in 2025 to USD 43.8 billion in 2030, with a CAGR of 21.3%. In the field of muscle regeneration, the Simone Spuler group at Charite Berlin has entered Phase I/II (registration to begin in 2024) with a satellite cell culture technology derived from human muscle-derived fiber fragments (HMFF). Epicrispr Biotechnologies is preparing for a Phase I trial for facioscapulohumeral muscular dystrophy (FSHD) using EPI-321, an AAV vector-based therapy. The SCOPE study provides a scientific basis for establishing a muscle regeneration pipeline specifically for OBPP and opens up opportunities for joint research and licensing between biotech companies and academic institutions in the field of pediatric regenerative medicine. The brachial plexus injury treatment market itself is expected to expand from USD 5.73 billion in 2024 to USD 9.22 billion in 2028 (CAGR of 12.6%).